NCT07296445 2025-12-29
LATITUDE
SDK Therapeutics, Inc.
Phase 3 Not yet recruiting
Clinical Trials
23 trialsNCT01409161 2025-12-17
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06882031 2025-11-18
Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic Leukemia
SDK Therapeutics, Inc.
Phase 1 Completed
NCT07187505 2025-09-23
Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia
Anhui Medical University
Phase NA Active not recruiting
NCT02688140 2025-02-26
TUD-APOLLO-064
Technische Universität Dresden
Phase 3 Completed
NCT04793919 2024-04-15
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
Associazione Italiana Ematologia Oncologia Pediatrica
Phase 2 Recruiting
NCT04996030 2024-01-23
A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia
Syros Pharmaceuticals
Phase 1 Suspended
NCT00551460 2023-01-10
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
SWOG Cancer Research Network
Phase 2 Completed
NCT05497310 2022-10-26
Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL
Hospital Universitario Dr. Jose E. Gonzalez
Phase 1/2 Unknown
NCT00482833 2022-10-12
APL0406
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 3 Completed
NCT03751917 2022-01-04
APL0618
Gruppo Italiano Malattie EMatologiche dell'Adulto
Unknown
NCT01404949 2021-11-30
Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02899169 2021-09-08
APL16
First Affiliated Hospital Xi'an Jiaotong University
Phase 3 Unknown
NCT01987297 2019-08-19
Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL
Shanghai Jiao Tong University School of Medicine
Phase 4 Unknown
NCT00528450 2016-01-29
Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT00670150 2015-10-27
New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia
University of Southern California
Phase 2 Withdrawn
NCT00504764 2014-10-28
Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)
PETHEMA Foundation
Phase 4 Completed
NCT00378365 2014-04-16
Acute Promyelocytic Leukemia 2006 (APL)
Assistance Publique - Hôpitaux de Paris
Phase 3 Unknown
NCT00985530 2013-10-30
Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia
Northwestern University
Phase 1 Terminated
NCT00003934 2013-06-05
Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia
National Cancer Institute (NCI)
Phase 3 Completed
NCT00008697 2013-04-12
Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia
Washington University School of Medicine
Phase 1/2 Completed
NCT00016159 2013-01-16
Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00196768 2007-10-23
Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic
German AML Cooperative Group
Phase 4 Unknown